Multi-omic approach characterises the neuroprotective role of retromer in regulating lysosomal health

Retromer controls cellular homeostasis through regulating integral membrane protein sorting and transport and by controlling maturation of the endo-lysosomal network. Retromer dysfunction, which is linked to neurodegenerative disorders including Parkinson’s and Alzheimer’s diseases, manifests in complex cellular phenotypes, though the precise nature of this dysfunction, and its relation to neurodegeneration, remain unclear. Here, we perform an integrated multi-omics approach to provide precise insight into the impact of Retromer dysfunction on endo-lysosomal health and homeostasis within a human neuroglioma cell model. We quantify widespread changes to the lysosomal proteome, indicative of broad lysosomal dysfunction and inefficient autophagic lysosome reformation, coupled with a reconfigured cell surface proteome and secretome reflective of increased lysosomal exocytosis. Through this global proteomic approach and parallel transcriptomic analysis, we provide a holistic view of Retromer function in regulating lysosomal homeostasis and emphasise its role in neuroprotection.

-Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy

Human research participants
Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender
Population characteristics

Recruitment
Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences
Behavioural & social sciences Ecological, evolutionary & environmental sciences For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
Data exclusions

Randomization
Blinding Source data are provided with this paper. The datasets generated during this study and minimum datasets required to interpret the data are included in the published article as Supplementary Data 1-8, and in public repositories. The mass spectrometry proteomics data generated in this study have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository under accession code PXD041323 (https://proteomecentral.proteomexchange.org/cgi/GetDataset? ID=PXD041323). The RNA-Seq data generated in this study have been deposited in the NCBI Gene Expression Omnibus under accession code GSE223292 (https:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223292). Mass spectrometry data were searched against the human Uniprot database retrieved on 2021-01-14, and updated with additional annotation information on 2021-11-15. Unprocessed blots and statistical data are included as Source Data.
Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data where this information has been collected, and consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex-and gender-based analyses where performed, justify reasons for lack of sex-and gender-based analysis.
Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above." Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
Identify the organization(s) that approved the study protocol.
Sample size calculations were not performed. All experiments were performed using at least 3 independent biological repeats.
No data were excluded from this study.
All quantified experiments were performed using at least 3 independent biological repeats. The reproducibility of findings is displayed by the individual datapoints on graphs, and all raw data is available in the source data.
Samples were allocated into experimental groups based on their genotype (e.g. wild-type, VPS35 KO clones and VPS35-GFP clone rescues). Control conditions were used throughout the manuscript to validate the effects of VPS35 and VPS29 KO. Where possible, VPS35-GFP and VPS29-GFP rescues are used to this to demonstrate reversion of observed phenotypes by re-expression of the deleted gene.
Blinding was not used in this study.
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.  Validation was provided through the manufacturer's data sheet (see above for manufacturer and product code information) and/or the published use and validation of the relevant antibodies by our and other research groups.
Where possible, we technically validate antibodies for genes which we target for CRISPR-mediated knockouts. For example, we validate the specificity of our VPS35, VPS29 and GFP antibodies through immunoblotting of the respective knockout cell lysates relative to control and rescue conditions.
HeLa, HEK293T and H4 cells were originally sourced from ATCC.
Authentication was provided by ATCC, and independently confirmed with Eurofins Genomics.
Parental HeLa, HEK293T and H4 cells used to generate clonal KO cells were tested for mycoplasma contamination, with no contamination detected.
No commonly misidentified cell lines were used.
All mice were used in the study were in a C57BL/6 genetic background. For both IUE and primary cortical neuron cultures, mothers were 8-12 weeks old. For primary cortical neuronal culture experiments, neurons were isolated at day E18.5. For IUE experiments, neocortical brain sections were taken at P14. The Vps35f/f mice were generated by injecting Vps35tm1a(EUCOMM)Hmgu embryonic stem (ES) cells (KO-first promoter-driven reporter-tagged insertion with conditional potential, purchased from International Mouse Phenotyping Consortium (IMPC), Germany) into the inner cell mass of C57BL/6J blastocysts. In Vps35tm1a(EUCOMM)Hmgu ES cell,